Securities Code: 002653
Securities Abbreviation: Haishike
Announcement No.: 2026-085
Haishike Pharmaceutical Group Co., Ltd.
Announcement on Opening Special Account for Raised Funds and Signing Supervision Agreement for Issuance of A Shares to Specific Objects in 2025
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed herein, and that there are no false records, misleading statements, or material omissions.
I. Basic Situation of Raised Funds
Approved by the China Securities Regulatory Commission's "Approval on the Registration of Haishike Pharmaceutical Group Co., Ltd. for Issuing Shares to Specific Objects" (Securities Regulatory License (2026) No. 78), Haishike Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") issued 20,974,510 shares of RMB ordinary shares (A shares) to specific objects at an issue price of ¥59.37 per share. The total amount of raised funds was RMB 1,245,256,658.70. After deducting various issuance expenses of RMB 14,041,932.61 (excluding VAT), the net amount of raised funds was RMB 1,231,214,726.09. The capital verification of the above raised funds was conducted by Xinyonghe Certified Public Accountants (Special General Partnership), which issued the "Haishike Pharmaceutical Group Co., Ltd. 2025 Annual Report on Capital Verification for Issuance of A Shares to Specific Objects" (XYZH/2026CDAA3B0751) on July 17, 2026.
II. Opening of Raised Funds Account and Signing of Supervision Agreement
To regulate the management and use of raised funds and protect the interests of investors, in accordance with the "Supervision Rules for Raised Funds of Listed Companies," the "Stock Listing Rules of the Shenzhen Stock Exchange," and the "Shenzhen Stock Exchange Listed Company Self-Regulatory Guidelines No. 1 - Normative Operation of Main Board Listed Companies," and the Company's "Management System for Raised Funds," the Company has opened a special account for raised funds. This account is used for the storage and use of raised funds for the "New Drug Research and Development Project." The Company has also signed a "Supervision Agreement for Raised Funds" with the sponsor and the commercial banks where the raised funds are deposited. The signing time and main content of the agreement comply with the "Supervision Rules for Raised Funds of Listed Companies," the "Stock Listing Rules of the Shenzhen Stock Exchange," the "Shenzhen Stock Exchange Listed Company Self-Regulatory Guidelines No. 1 - Normative Operation of Main Board Listed Companies," and the Company's "Management System for Raised Funds."
As of August 9, 2026, the status of the Company's raised funds special accounts and fund storage is as follows: